InterVenn Malaysia and Agilent signing an MOU. From left (seated): Fadzhairi Jabar, InterVenn General Manager and Soh Lam Seng,  Agilent Malaysia Country Manager, Laboratory Solutions Sales.
From left (back) Muhamad Husni Md Zain, Acting Head of TPM Nexus Sdn Bhd, and Robin Philp, Agilent Southeast Asia Academia and Collaborations Manager, Laboratory Solution Sales.

KUALA LUMPUR, Oct 19 (Bernama) --  InterVenn, a San Francisco based biotechnology company innovating precision medicine and diagnostic products using next-generation mass spectrometry coupled to a proprietary artificial Intelligence/machine learning-based data processing engine, has announced a collaboration with Agilent Technologies, a leading provider of bio-analytical and scientific instrumentation.
 
This strategic partnership gathers the strength of both parties to develop cutting edge precision diagnostic tools by investigating targeted glycoproteomic biomarkers for diseases such as cancer.
 
The focus of this collaboration will be on diseases common in Southeast Asia, and the premises for this development work will be at InterVenn Malaysia’s laboratory located at Technology Park Malaysia (TPM) in KL. Their decision to conduct their clinical study in TPM is testament to the park’s comprehensive soft and hard infrastructure that supports scientific research works.
 
InterVenn Malaysia was represented by General Manager, Fadzhairi Jabar and Soh Lam Seng,  Malaysia Country Manager, Laboratory Solutions Sales for Agilent. Also present at the signing ceremony were Muhamad Husni Md Zain, Acting Head of TPM Nexus Sdn Bhd,  subsidiary of TPM Corporation and Robin Philp, Southeast Asia Academia and Collaborations Manager, Laboratory Solution Sales, Agilent.
 
“We are very pleased to welcome Agilent as a strategic partner to our research and development effort. This partnership goes a long way toward realizing InterVenn’s long-held vision to establish a Center of Excellence of Glycoproteomics for Southeast Asia at its premises in Kuala Lumpur that will not only allow InterVenn to accelerate its collaborative work with leading academics in Malaysia and the region, but will also serve as a training and demonstration center for aspiring scientists and start-up companies in Southeast Asia.” said Aldo Carascoso, CEO of InterVenn.

“Most importantly, this new laboratory will be the first of its kind offering diagnostic tools based on the science of glycoproteomics for the healthcare needs of the more than 650 million citizens of the region. The collaboration will, without doubt, place both partners on the leading edge of both innovation and public service” he added.
 
According to Robin Philp, Agilent’s Academia and Collaborations Manager, “Agilent is very excited to become a strategic partner with InterVenn in the establishment of a Centre of Excellence of Glycoproteomics. The opportunity to engage in the area of clinical measurement and especially for diseases such as cancer is of great importance and of societal benefit.
 
The forward looking vision to extend the collaboration with academic institutions is also one that is shared by Agilent in its capacity to work with seats of learning and education. We wholeheartedly embraces this opportunity and looks forward to a successful outcome” he added.
 
TPM is an agency under the auspices of Ministry of Science, Technology and Innovation to promote national innovation and knowledge-based economy. It has an integrated infrastructure, facilities and support services to assist technopreneurs and entrepreneurs who are keen to commercialize their ideas in the three industry clusters, namely, ICT, Engineering and Biotechnology.
 
TPM is the co-secretariat of PENJANA’S National Technology and Innovation Sandbox which allows researchers, innovators, startups and high-tech entrepreneurs to test their products, services, business models and delivery mechanisms in a live environment.

About InterVenn Biosciences
 
InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression. For more information about InterVenn Biosciences, please visit the company’s website.
 
For partnership and collaboration, please contact: info@venn.bio

SOURCE: Technology Park Malaysia Corporation Sdn Bhd

FOR MORE INFORMATION, PLEASE CONTACT: 
Email: info@venn.bio

--BERNAMA